Stock traders buy large volume of call options from Theravance Biopharma (NASDAQ: TBPH)
Theravance Biopharma, Inc. (NASDAQ: TBPH) was the target of unusual options trading activity on Monday. Stock traders acquired 4,344 call options on the stock. This represents an increase of approximately 356% over the average volume of 952 call options.
NASDAQ TBPH shares traded up $ 1.20 in Monday’s midday session, reaching $ 12.25. 456,201 shares of the stock traded for an average volume of 703,828. The company has a market capitalization of $ 902.80 million, a PE ratio of -3.49 and a beta of 0.84. Theravance Biopharma has a one-year minimum of $ 6.10 and a one-year maximum of $ 22.74. The stock has a 50-day moving average of $ 9.03.
Theravance Biopharma (NASDAQ: TBPH) last released its quarterly results on Tuesday, November 2. The biopharmaceutical company reported ($ 0.48) earnings per share for the quarter, beating Thomson Reuters consensus estimate of ($ 0.60) by $ 0.12. The company posted revenue of $ 13.19 million for the quarter, compared to analysts’ expectations of $ 13.55 million. In the same quarter of the previous year, the company posted EPS ($ 1.16). Analysts expect Theravance Biopharma to post earnings per share of -2.84 for the current year.
A number of analysts recently commented on the headline. SVB Leerink lowered its price target on Theravance Biopharma shares from $ 29.00 to $ 10.00 and established an “outperformance” rating on the share in a report released on Thursday, September 16. Cowen reduced his target price on Theravance Biopharma from $ 14.00 to $ 8.00 and established a “market performance” rating for the company in a research report released on Wednesday, September 15. Zacks Investment Research downgraded Theravance Biopharma from a “buy” rating to a “keep” rating and set a target price of $ 7.50 for the company. in a research report on Wednesday, September 22. Robert W. Baird reduced his target price on Theravance Biopharma from $ 10.00 to $ 7.00 and established a “neutral” rating for the company in a research report on Thursday, September 16. Finally, Needham & Company LLC downgraded Theravance Biopharma from a “buy” rating to a “keep” rating in a research report released on Wednesday, September 15. Two analysts rated the stock with a sell rating, five issued a conservation rating and two gave the company a buy rating. According to data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Hold” and a consensus target price of $ 10.50.
A number of hedge funds have recently increased or reduced their stakes in the company. Madison Avenue Partners LP acquired a new stake in Theravance Biopharma in the third quarter for a value of approximately $ 36,478,000. Point72 Asset Management LP acquired a new stake in Theravance Biopharma in the third quarter for a value of approximately $ 25,201,000. Camber Capital Management LP acquired a new stake in Theravance Biopharma in the third quarter for a value of approximately $ 18,500,000. Maven Securities LTD acquired a new stake in Theravance Biopharma in the second quarter for a value of approximately $ 20,125,000. Finally, FMR LLC increased its stake in Theravance Biopharma shares by 10.9% during the second quarter. FMR LLC now owns 10,791,863 shares of the biopharmaceutical company valued at $ 156,698,000 after purchasing an additional 1,061,697 shares during the period. Institutional investors and hedge funds hold 72.77% of the company’s shares.
About Theravance Biopharma
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ selective drugs. Its goal is to launch a new generation of small molecule drugs designed to better meet the needs of patients. His research focuses on the areas of inflammation and immunology. In pursuit of its goal, Theravance Biopharma applies knowledge and innovation at every stage of its activities and uses its internal capacities and those of partners around the world.
Featured article: If I buy stocks through a brokerage account, am I the registered owner?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Theravance Biopharma now?
Before you consider Theravance Biopharma, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the top five stocks that top analysts quietly whisper to their clients to buy now before the market in general takes hold … and Theravance Biopharma was not on the list.
While Theravance Biopharma currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here